Hendrik Peter Scholl, Chief Medical Officer at Belite Bio, sold BLTE on Oct 1, 2026
Data as of Oct 16
- Traded
- Oct 1, 2026
- Disclosed
- Oct 5, 2026
- Filed
- 4 days after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
BLTE since disclosure
−10.3%
after the sale
Similar stocks (XLV) since disclosure
+5.6%
XLV — its sector index fund
Change in closing price from Oct 5, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.
Other trades in the same filing
- ▼ SELLHendrik Peter Scholl Chief Medical OfficerBLTE Belite Bio, Inc$2Kdisclosed Oct 5 · filed 4 days after the trade
- ▼ SELLHendrik Peter Scholl Chief Medical OfficerBLTE Belite Bio, Inc$8.3Kdisclosed Oct 5 · filed 4 days after the trade
- ▼ SELLHendrik Peter Scholl Chief Medical OfficerBLTE Belite Bio, Inc$4Kdisclosed Oct 5 · filed 4 days after the trade
- ▼ SELLHendrik Peter Scholl Chief Medical OfficerBLTE Belite Bio, Inc$19.9Kdisclosed Oct 5 · filed 4 days after the trade
- ▼ SELLHendrik Peter Scholl Chief Medical OfficerBLTE Belite Bio, Inc$13.1Kdisclosed Oct 5 · filed 4 days after the trade
- ▼ SELLHendrik Peter Scholl Chief Medical OfficerBLTE Belite Bio, Inc$340disclosed Oct 5 · filed 4 days after the trade
- ▼ SELLHendrik Peter Scholl Chief Medical OfficerBLTE Belite Bio, Inc$32.7Kdisclosed Oct 5 · filed 4 days after the trade